The Pennsylvania Superior Court has ruled that a $70 million jury verdict against Johnson & Johnson subsidiary Janssen and in favor of a child allegedly injured by antipsychotic drug Risperdal was not excessive, and has also remanded the case for a second look at whether there should be a punitive damages trial.

A three-judge panel of the appellate court unanimously ruled in A.Y. v. Janssen Pharmaceuticals to uphold Philadelphia Court of Common Pleas Judge Paula Patrick‘s judgment entered after the jury sided with A.Y., a male plaintiff who claimed that the anti-psychotic medication caused him to grow excessive breast tissue.